AbbVie's is reporting positive study results from phase 2 trials evaluating its next-generation oral therapy for rheumatoid arthritis and based on those results, the company plans to move ABT-494 into ...
You might not have noticed it, but AbbVie (NYSE: ABBV) is on a roll -- at least when it comes to winning drug approvals. Since the beginning of 2019, the big biotech has racked up U.S. Food and Drug ...
TORONTO, June 05, 2020 (GLOBE NEWSWIRE) -- TALTZ ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually ...
TORONTO, June 14, 2019 /CNW/ - Eli Lilly and Company announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active ...
INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus ...
TORONTO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company announced the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of TALTZ® (ixekizumab) versus Humira® (adalimumab) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback